Source Fact: Financial Supervisory Service DART / 2024-11-20
Disclosure Type: Conclusion of Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has secured a Contract Manufacturing Organization (CMO) agreement worth approximately KRW 178 billion (USD 127.85 million) with a European-based pharmaceutical company, spanning until the end of 2031.
📊 1. [Summary of Core Disclosure & Key Figures]
- Contract Name: Contract Manufacturing Agreement (Pharmaceuticals)
- Contract Amount: KRW 177,967,200,000 (Fixed amount: USD 127,850,000)
- Applied FX Rate: KRW 1,392.00 per USD (Based on the initial standard proxy rate on November 20, 2024)
- Ratio to Recent Sales: 4.82% of the 2023 consolidated annual revenue (KRW 3.69T)
- Counterparty: A pharmaceutical company located in Europe (Identity remaining confidential until December 31, 2031, due to trade secrecy)
- Contract Period: November 14, 2024 ~ December 31, 2031
- Execution (Order) Date: November 20, 2024
📈 2. [Expert Insight: Implications for Investors]
- Securing Long-Term Revenue Streams: This contract is a long-term manufacturing agreement spanning roughly seven years. It could serve as a positive factor for the company’s mid-to-long-term operational Fundamental by expanding the order backlog and stabilizing factory utilization rates.
- Revenue Impact Assessment: The contract size represents 4.82% of the company’s recent annual revenue. Rather than acting as a massive earnings surprise triggering an immediate spike in short-term performance, it is likely to be interpreted as a steady addition to the company’s sustainable growth momentum.
- Investor Consideration: Since the fixed contract value is designated in USD, the actual recognized revenue in KRW may fluctuate depending on FX volatility at the time of delivery. Furthermore, because specific details regarding the counterparty and product remain undisclosed due to confidentiality clauses until late 2031, market participants should take into account this information asymmetry when assessing the deal.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics has added another milestone to its global order rally. While this order is a mid-sized deal representing around 5% of annual revenue, the key takeaway is its extended duration through 2031. Continuously expanding CMO references in the European market—home to many global big pharma companies—improves mid-to-long-term visibility for utilizing Plant 4 and the upcoming Plant 5. Although the counterparty remains masked under a confidentiality agreement, the fact that it is a USD-denominated fixed contract indicates that a prolonged strong-dollar environment could potentially offer upside in FX-driven profitability moving forward.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
